Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia [PDF]
Clinical Interventions in Aging, 2015 Karen Seiter, Aleksandra Mamorska-DygaDepartment of Medicine, Division of Hematology/Oncology, New York Medical College, Valhalla, NY, USA Abstract: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries ...
Seiter K, Mamorska-Dyga A
doaj +1 more source
Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma [PDF]
Haematologica, 2016 Obinutuzumab (GA101) is a type II, glycoengineered anti-CD20 monoclonal antibody for the treatment of hematologic malignancies. Obinutuzumab has mechanisms of action that are distinct from those of rituximab, potentially translating into improved ...
Guillaume Cartron +6 more
doaj +2 more sources
Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
Biologics: Targets & Therapy, 2015 Sonia Cerquozzi,1 Carolyn Owen2 1Department of Hematology, University of Calgary, 2Department of Hematology, Tom Baker Cancer Centre, Calgary, AB, Canada Abstract: The introduction of targeted therapy against CD20+ with the monoclonal antibody rituximab
Cerquozzi S, Owen C
doaj +1 more source
Obinutuzumab-induced severe acute thrombocytopenia: a case report and literature review
Frontiers in ImmunologyObinutuzumab is a humanized type II anti-CD20 monoclonal antibody that is widely used in B-cell lymphomas including follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).
Kun Kou, Qiaolin Zhou, Lijun Du, Fang Xu
doaj +2 more sources
The clinical development of obinutuzumab for the treatment of follicular lymphoma
Cancer Management and Research, 2017 Barbara Ma,1 Chaitra Ujjani2 1Department of Medicine, 2Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC, USA Abstract: Impressive progress has been made in recent decades for advanced-stage follicular lymphoma ...
Ma B, Ujjani C
doaj +1 more source
Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12.
, 2016 [First paragraph] Obinutuzumab, an afucosylated, type 2 anti-CD20 antibody, showed superior results to rituximab in a head-to-head comparison in combination with chlorambucil in the first-line treatment of chronic lymphocytic leukaemia (CLL) patients ...
M. Lyttelton (7738970) +5 more
core +7 more sources
Frontiers in ImmunologyObjectiveRituximab remains the standard-of-care anti-CD20 therapy for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Obinutuzumab, a next-generation, glycoengineered anti-CD20 monoclonal antibody with enhanced B-cell-depleting ...
Wenyi Wu, Juan Wang, Sheng Chen
doaj +2 more sources
Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real-World Study. [PDF]
Cancer MedIn treatment‐naïve CLL, a shortened obinutuzumab infusion was as safe as standard infusion, did not increase infusion‐related reactions, and significantly reduced chair time, improving outpatient unit efficiency. ABSTRACT Background Obinutuzumab‐based regimens are established frontline treatments for chronic lymphocytic leukemia (CLL), but infusion ...
Écsiová D +6 more
europepmc +2 more sources
Obinutuzumab-induced acute thrombocytopenia and leukopenia in ANCA-associated glomerulonephritis: case report and literature review [PDF]
Frontiers in ImmunologyObinutuzumab is a humanized type II anti-CD20 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity. It is widely used in B-cell malignancies and is increasingly being explored in autoimmune diseases such as lupus nephritis. The main
Yiming Jin, Yiqi Huang, Xiaomiao He
doaj +2 more sources
Clinical Application of Obinutuzumab for Treating Chronic Lymphocytic Leukemia
Drug Design, Development and Therapy, 2019 Chunyan Luan, Baoan ChenDepartment of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu Province 210009, People’s Republic of ChinaCorrespondence: Baoan ChenDepartment of Hematology and Oncology ...
Baoan Chen
exaly +2 more sources